This trial is evaluating whether Senicapoc will improve 3 primary outcomes and 16 secondary outcomes in patients with Mild Cognitive Impairment (MCI). Measurement will happen over the course of Baseline, Week 52.
This trial requires 55 total participants across 2 different treatment groups
This trial involves 2 different treatments. Senicapoc is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
While the American Psychological Association no longer considers MCI to be a form of dementia, the mci prevalence is comparable to or higher than the prevalence of MCI-I in the general population. While the American Psychological Association no longer considers MCI to be a form of dementia, the mci prevalence is comparable to or higher than the prevalence of MCI-I in the general population. While the American Psychological Association no longer considers MCI to be a form of dementia, the mci prevalence is comparable to or higher than the prevalence of MCI-I and MCI-H in the general population.
The current studies suggest that mci is not a permanent or even long term condition that cannot be cured. Better understanding of the heterogeneity of MCI will contribute to a more specific characterization, better treatment, and improved health-related outcomes.
Some signs of mild cognitive impairment (mci) include confusion, disorientation, and not remembering how to do things. Other signs include memory and attention problems. Other signs of mci could include trouble sleeping, restless legs, and trouble controlling the eyes. If symptoms are serious, a doctor or family doctor can administer a dementia screening test.\n
mci has distinct clinical, neuropsychological and neuroimaging characteristics from MCI. mci is associated with more rapid and sustained neuropsychological decline than MCI. The development of MTS is an independent factor of dementia. The diagnostic utility of MTS should be further investigated especially for early detection of dementia/MCI.
It is difficult to say the exact cause of MCI and it can't necessarily be found by screening. Some factors that increases the risk of getting MCI include obesity, alcohol/tobacco/drug use, viral infections causing acute inflammatory brain damage, immunological defects, brain damage from stroke or traumatic brain injury, some autoimmune, neurodegenerative, inflammatory/inflammatory neurodegenerative and neurovascular disorders. However, some of these possible causes may have common causal factors such as viral infections or immune system dysfunction.
For older adults, cognitively intact people, treatments that help maintain and even improve cognition are critical. Some commonly used treatments have been shown to have the strongest evidence for their benefits, while others have strong benefit but weaker evidence. In the absence of good evidence, this review will highlight a range of treatments, based on the type of treatment and the individual patient. The focus of this review is on drugs and therapies with proven benefit, and only as a general guide; there is still a need for high quality clinical research that could help clarify the most effective treatment for older people with mci.
Findings from a recent study suggest that deficits in executive functions make a large contribution to early stage mci patients. Cognitively normal individuals with mild mci are also more likely to suffer from severe impairments in executive functions than healthy controls. Reduced executive functioning in mci correlates with age, schooling, and employment history. Findings from a recent study of the correlation analyses between patient and control groups show that executive deficiencies increase the risk of developing cognitive deficits. Executive defects in mci correlate with increased executive difficulties and increased severity of the executive deficits, such as reduced efficiency in the inhibition of inappropriate responses.
Results from a recent paper, of people with mild to moderately severe cognitive impairment and age >75, the medication did not result in a clinically important increase in deaths or hospitalisations. Senicapoc does not have an increased risk of dementia or agitation.
Mild cognitive impairment (mci) is associated with an increase of disability and an impact on patients' social life of daily living, as well as an increase in the need for a caregiver.
About 60% of patients experienced [sudden hearing loss] side effects. Because patients with [older] age or [more] severe medical conditions were more likely to experience such [side effects], clinicians should more often consider a [hearing test] when [observing a patient].
In families with an mci diagnosis, the risk of having a diagnosis of Alzheimer's disease is approximately three times increased per affected level. In families with an affected spouse, the risk for an affected child is approximately one and a half times increased. Thus, if there is an mci diagnosis in an affected family member, it may be prudent to consider a family history of Alzheimer's disease for that affected person and, if indicated, arrange clinical testing.
Findings from a recent study indicate that senicapoc's effectiveness and tolerability in treating AD is similar to that observed with placebo. Findings from a recent study do not indicate any specific reason why senicapoc treatment is ineffective or safe in AD patients.